Results through Q2 2025 PRESENTATION INVESTOR Peter Hoetzinger, Co CEO & President FORWARD - LOOKING STATEMENTS This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Century Casinos, Inc. (together with its subsidiaries, the "Company", "we", "us", "our") may make other written and oral ...

Core Viewpoint - Ascot Resources Ltd. has decided to place the Premier Gold Project on care and maintenance due to unsuccessful negotiations with its mining contractor and delays in mobilizing a mining fleet, impacting the timeline for restarting operations [3][4]. Company Update - Ascot has been in negotiations with Procon Mining regarding proposed price increases for mining services, but these discussions have not yielded a satisfactory cost structure [2][3]. - The delays in mobilizing a mining fleet to the Big Missouri deposit, a critical component of the restart plan, have led to the decision to pause operations at the Premier Gold Project [3][4]. - The management team is assessing strategic alternatives to advance the project towards sustainable production, with a Special Committee appointed to lead this review process [5]. Operational Challenges - The new management team has made progress in the past five months, but operational challenges have arisen that require time and capital to address [5]. - The mill is now expected to remain non-operational beyond the previously planned early August timeline due to these challenges [3][4]. Strategic Review - The Special Committee has retained financial advisors to explore various strategic alternatives, although there is no assurance that this process will lead to a transaction [5].

Core Viewpoint - AYR Wellness Inc. has delayed the filing of its interim financial statements for the period ended March 31, 2025, primarily due to ongoing negotiations with creditors and assessment of debt obligations [1][2] Group 1: Financial Filings and Delays - The interim financial statements, management's discussion and analysis, and related CEO and CFO certificates were not filed by the anticipated date of June 13, 2025 [1] - The delay is attributed to negotiations with creditors and the evaluation of accounting classifications of certain debt obligations [2] - AYR is working to complete the interim filings as soon as possible and will provide an update on the timing by June 27, 2025 [4] Group 2: Regulatory Actions - The Ontario Securities Commission has issued a failure-to-file cease-trade order (FFCTO), prohibiting all trading in AYR's securities in Canada [3] - The FFCTO will remain in effect until AYR completes and files the interim filings and meets all Canadian Securities Exchange requirements [3] Group 3: Company Operations - Despite the FFCTO, AYR does not expect any impact on its ability to operate in the ordinary course [4] - AYR Wellness operates as a vertically integrated U.S. multi-state cannabis business with over 90 licensed dispensaries [6]

Core Viewpoint - AYR Wellness Inc. is unable to meet the May 30, 2025 deadline for filing its interim financial report due to ongoing negotiations regarding its debt obligations and has applied for a cease-trade order [1][3][4] Group 1: Financial Reporting and Compliance - AYR Wellness Inc. announced it will not meet the Filing Deadline for its interim financial report for the period ended March 31, 2025, as required under Canadian securities laws [1] - The Ontario Securities Commission (OSC) will issue a failure-to-file cease-trade order (CTO) instead of a management cease trade order (MCTO), which will prohibit trading in AYR's securities across all Canadian jurisdictions until the interim filings are completed [4] Group 2: Strategic Review and Debt Negotiations - The company is undergoing a strategic review process due to upcoming payment obligations to creditors and has retained Moelis & Company LLC as its exclusive investment banker to explore capital structure alternatives [2] - AYR is negotiating with a committee representing over 50% of its outstanding senior secured notes due December 10, 2026, as part of its broader strategic review [2] Group 3: Operational Impact and Future Expectations - The company does not expect the CTO to impact its ability to operate normally and anticipates completing and filing the interim financial report by June 13, 2025 [5] - AYR will provide an update on the anticipated timing for filing the documents if not completed by the expected date [5] Group 4: Company Overview - AYR Wellness Inc. is a leading vertically integrated U.S. multi-state cannabis operator with over 90 licensed dispensaries and a commitment to delivering high-quality cannabis products [7]

Core Viewpoint - Keros Therapeutics emphasizes the importance of its board in overseeing the strategic review process and urges stockholders to support its director nominees to maximize company value amid challenges posed by ADAR1's campaign [1][2][3]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [10][11]. - The company is advancing several product candidates, including cibotercept for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept for cytopenias [10][11]. Board Composition and Strategy - The Keros Board consists of nine independent directors, including four stockholder representatives, bringing diverse expertise in biotechnology, drug development, and capital allocation [7]. - The board is currently engaged in a strategic alternatives review process, which is seen as a constructive step to address shareholder concerns and maximize value [3][8]. Proxy Advisory Firm Recommendations - Glass Lewis & Co. has recommended that Keros stockholders vote "FOR" all three of the company's director nominees, recognizing their qualifications and the board's efforts to enhance stockholder value [1][3]. - The board's decision to retain flexibility through a formal strategic review is viewed as a reasonable approach, contrasting with ADAR1's aggressive campaign [3][5]. Response to ADAR1's Campaign - Keros has responded to claims made by ADAR1, stating that the recent share price decline is primarily due to clinical development risks rather than board mismanagement [3][4]. - The company argues that ADAR1 has not provided compelling evidence against the board members and that the board's actions have been in the best interests of all stockholders [3][6].